WATERTOWN, Mass.--(BUSINESS WIRE)--
pSivida Corp. (NASDAQ:PSDV),
a specialty pharmaceutical company that is a leader in developing
sustained release drugs for treatment of back-of-the-eye diseases, will
present at the 4th Annual Biosimilars & Biobetters Conference
being held October 1 and 2 in London.
Dr. Paul Ashton, president and CEO of pSivida, will discuss "A Simple
Route to Biobetters" providing delegates insight into sustained delivery
of biologics. Additional case study presentations include speakers from
pharmaceutical companies such as Novartis, Pfizer, Eli Lilly & Company,
Roche and Merck Millipore, among others.
pSivida is developing Tethadur™, a sustained-release delivery system of
nanostructured porous silicon that has the potential to deliver
proteins, peptides and antibodies on a pre-determined controlled basis.
The conference is expected to touch on catalysts, such as patent
expirations, which are propelling increased interest in and development
of biological therapeutic programs by the pharmaceutical industry. More
information on the conference is available at the conference website: http://www.biosimilars-biobetters.co.uk.
About pSivida
pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained
release, drug delivery products designed to deliver drugs at a
controlled and steady rate for months or years. pSivida is currently
focused on treatment of chronic diseases of the back of the eye
utilizing its core technology systems, Durasert™ and BioSilicon™. The
injectable, sustained release micro-insert ILUVIEN® for the treatment of
chronic DME considered insufficiently responsive to available therapies,
licensed to Alimera Sciences, Inc., has received marketing authorization
in Austria, France, Germany, Portugal, Spain and the U.K. and is
awaiting authorization in Italy. Alimera has resubmitted the New Drug
Application for ILUVIEN for DME to the U.S. Food and Drug
Administration. pSivida plans to institute pivotal Phase III clinical
trials for the treatment of posterior uveitis, a chronic back-of-the-eye
disease, with the same micro-insert as ILUVIEN for DME. An
investigator-sponsored clinical trial is ongoing for an injectable,
bioerodible micro-insert to treat glaucoma and ocular hypertension.
pSivida's FDA-approved Retisert® licensed to Bausch & Lomb Incorporated
provides long-term, sustained drug delivery to treat posterior uveitis.
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM
ACT OF 1995:
Various statements made in this release are forward-looking, and are
inherently subject to risks, uncertainties and potentially inaccurate
assumptions. All statements that address activities, events or
developments that we intend, expect or believe may occur in the future
are forward-looking statements. The following are some of the factors
that could cause actual results to differ materially from the
anticipated results or other expectations expressed, anticipated or
implied in our forward-looking statements: uncertainties with respect
to: determination of the price and reimbursement conditions for ILUVIEN
in France; Alimera's ability to obtain regulatory approval for, and if
approved, to finance, successfully commercialize and achieve market
acceptance of, and generate revenues to pSivida from, ILUVIEN for DME in
the U.S.; Alimera's ability to finance, achieve additional marketing
approvals, achieve appropriate pricing and reimbursement and
successfully commercialize and achieve market acceptance of, and
generate revenues to pSivida from, ILUVIEN for DME in the EU; the
success of Phase III posterior uveitis trials including efficacy, side
effects and risk/benefit profile of the posterior uveitis micro-insert
and pSivida's ability to finance and complete the trials and receive
marketing approvals; initiation, financing and success of Latanoprost
Product Phase II trials and exercise by Pfizer of its option;
development of products using Tethadur and BioSilicon; initiation and
completion of clinical trials and obtaining regulatory approval of
product candidates; adverse side effects; ability to attain
profitability; ability to obtain additional capital; further impairment
of intangible assets; fluctuations in operating results; decline in
royalty revenues; ability to, and to find partners to, develop and
market products; termination of license agreements; competition and
other developments affecting sales of products; market acceptance;
protection of intellectual property and avoiding intellectual property
infringement; retention of key personnel; product liability;
consolidation in the pharmaceutical and biotechnology industries;
compliance with environmental laws; manufacturing risks; risks and costs
of international business operations; credit and financial market
conditions; legislative or regulatory changes; volatility of stock
price; possible dilution; possible influence by Pfizer; absence of
dividends; and other factors described in our filings with the SEC.
Given these uncertainties, readers are cautioned not to place undue
reliance on such forward-looking statements. Our forward-looking
statements speak only as of the dates on which they are made. We do not
undertake any obligation to publicly update or revise our
forward-looking statements even if experience or future changes makes it
clear that any projected results expressed or implied in such statements
will not be realized.
Follow pSivida on social media:
Twitter: https://twitter.com/pSividaCorp
Facebook: https://www.facebook.com/pages/PSivida-Corp/544893792199562
LinkedIn: http://www.linkedin.com/company/psivida
Google+: https://plus.google.com/u/0/b/113754643626984244726/113754643626984244726/posts
The President's Blog: http://www.thechairmansblog.com/paul-ashton
IN US:
Martin E. Janis & Company, Inc.
Beverly Jedynak,
President
312-943-1123; 773-350-5793 (cell)
bjedynak@janispr.com
or
IN
AUSTRALIA:
pSivida Corp.
Brian Leedman, Vice President,
Investor Relations
+61 (0) 41 228 1780
brianl@psivida.com
Source: pSivida Corp.
News Provided by Acquire Media
